Please wait...

You selected inventions in category Biotech

  • A NEW DRUG FOR THE PREVENTION AND TREATMENT OF HERPES SIMPLEX VIRUS HSV-1A NEW DRUG FOR THE PREVENTION AND TREATMENT OF...
      Preview
      Description

      Herpes simplex virus 1 (HSV-1), is one of the most commonly encountered pathogens in humans. The most recent statistics indicate that approximately 50-90% of the world population is HSV-1 seropositive. The most common primary infections are cold sores occurring mainly on the face (especially the skin, tongue and lips). However, infection with HSV-1 may also lead to severe diseases such as inflammation of the eye or encephalitis. These diseases are characterized by severe course and may cause permanent adverse health effects (e.g. blindness), and even death.

      Currently, there are several antiviral drugs, which are active against pathogens belonging to the Herpesviridae family. These drugs reduce the frequency and severity of relapses and also alleviate bothersome symptoms during the primary infection. Although they are usually only effective for the initial infection, they do not eliminate a virus in a latent state and thus do not protect a person before re-emergence of symptoms. There has also been increasing emergence of drug resistant viral strains. Thus, there is a need to find a new approach to developing effective treatment of HSV-1 infection. The new invention of the Jagiellonian University, which is the subject of the proposed offer, discloses a new drug for treatment of herpes simplex virus (HSV-1) infection.

      The main advantages of the offered drug are:
       confirmed ability to efficient bind of herpes simplex virus (HSV-1)
      and inhibit its replication in vitro,
       low-toxicity of the drug in vitro,
       the possibility to apply as an ointment or solution administrated either topically to the skin or eye, orally, intraperitoneally or intravenously.

      The offered invention is subject of a patent application. Further research
      and development are conducted at the Faculty of Chemistry and Faculty of Biochemistry, Biophysics and Biotechnology of the Jagiellonian University. Currently, the Centre for Technology Transfer CITTRU is looking for partners interested in the development of the invention and its commercial application.

      More information:
      PhD Klaudia Polakowska – Technology Transfer Officer
      phone. +48 12 663 3832, +48 519 329 129, klaudia.polakowska@uj.edu.pl

      Full details Contact close
    • A new drug for the prevention and treatment of human influenza A virus IAV human metapneumovirus hMPV and human rhinoviruses HRVA new drug for the prevention and treatment of...
        Preview
        Description

        Potential drug: a modified polyallylamine derivative

        Application: prevention and treatment of human influenza A virus (IAV), human metapneumovirus (hMPV) and human rhinoviruses (HRV)

        Influenza is an acute infectious disease caused by viruses belonging to the Orthomyxoviridae family, and classified into three types: A, B and C. This classification is based on antigenic differences between the major virion proteins, e.g. M protein and nucleoprotein NP. These types differ in terms of epidemiological properties.

        Influenza A virus (IAV) causes acute and chronic respiratory infections. It is a major respiratory pathogen of humans and animals. A period of frequent influenza infections occurs each winter (seasonal flu, the highest incidence occurring
        in January/February). Only type A influenza virus causes epidemics and pandemics because of antigenic shift that is multiple changes in the various genome segments resulting from reassortment of different strains of the virus.

        According to the World Health Organization (WHO) infections with influenza
        and influenza-like viruses occur globally with an annual attack rate estimated at 5%-10% in adults and 20%-30% in children. Worldwide, these annual epidemics are estimated to result in about 3 to 5 million cases of severe illness, and about 250 000 to 500 000 deaths. The most severe infections develop in children under two years of age, in the elderly aged 65 or older and in those with compromised immunity. WHO recommends vaccination against the influenza virus as the most effective way to prevent infections. On the other hand, because of a large variability of the virus, the difficulty in obtaining sufficient number of vaccines before the epidemic wave, and not always satisfactory efficacy of the vaccine and anti – influenza drugs, the disease still represents an important medical and epidemiological problem. Therefore, new effective drugs for the anti-influenza treatment are needed.

        The new invention of the Jagiellonian University, which is the subject
        of the proposed offer, discloses a new drug for the treatment of human A virus (IAV) infection.

        Human metapneumovirus (hMPV) was identified in 2001, however, it was proved that infections with this pathogen have occurred in the human population for
        at least 50 years now. It is the only known Pneumovirus which infects humans and causes both upper and lower respiratory tract infections. Respiratory infections caused by hMPV have been reported in patients of every age and gender,
        but children under 5 years are most likely to be susceptible to infections caused
        by hMPV. The clinical manifestations of hMPV disease are flu-like symptoms such
        as runny nose, cough, sore throat and high fever. The virus is widespread, and is found on all continents. Late winter and early spring is the epidemic peak of hMPV infections. More serious symptoms, including severe lower respiratory tract infections, are found mainly in young children and infants under 5 years
        of age, elderly individuals above 60 years of age, and immunocompromised patients, whereas immunocompetent adults present mostly flu-like illnesses or cold symptoms.
        So far, no other drug has been approved for inhibition and prevention
        of infections caused by hMPV. By 2012, the only drugs with broad spectrum
        of activity (such as ribavirin and immunoglobulins) have been used to treat very acute, severe hMPV infections of patients after lung transplantation. The new invention of the Jagiellonian University, which is the subject of the proposed offer, discloses a new drug for treatment of human metapneumovirus (hMPV) infection.

        The human rhinovirus (HRV) belongs to the smallest known viruses (their diameter does not exceed 30 nm). During the year, particularly in winter and spring, it causes infections of the upper respiratory tract with humans, appearing as the common cold. Rhinoviruses also cause otitis media, sinusitis and inflammations of the lower respiratory tract, including bronchi

        Full details Contact close
      • A new method of obtaining chlorophyll derivatives using genetically modified bacteriaA new method of obtaining chlorophyll derivatives...
          Preview
          Description

          The subject of this offer is a new method of preparation of plant enzymes used to modify chlorophylls and bacteriochlorophylls. Plant enzymes from the chlorophyllase family are produced in genetically modified strain of Escherichia coli and obtained in a powdered form, which can then be used repeatedly to modify chlorophylls and bacteriochlorophylls. The method can be applied in manufacturing of chlorophyll-based drugs for photodynamic therapy, but also in industrial processes such as de-colourisation of plant oils.

          Full details Contact close
        • Amylase assay hemolysis interference-freeAmylase assay hemolysis interference-free
            Preview
            Description

            Although the assessment of α-amylase is an essential part of the diagnostic workout of several pancreatic and extra-pancreatic disorders, its enzymatic activity is significantly reduced in the presence of cell-free hemoglobin such as in samples with spurious hemolysis, due to chemical and spectrophotometric interference. We developed a new reagent that provides reliable results on hemolyzed biological specimens.
            The clinical applications of the experimental reagent include α-amylase assessment in hemolyzed samples, in urine and other biological fluids contaminated with lysed erythrocytes, or in patients under frequent transfusions and hemoglobin-based blood substitutes therapy. The formulation of this reagent could be adapted for other clinical chemistry or immunochemistry assays.
            See publication at: http://www.ncbi.nlm.nih.gov/pubmed/23420287

            Full details Contact close
          • ANTI-HISTIDINE TAG DNA APTAMERS FOR BIOTECHNOLOGICAL APPLICATIONSANTI-HISTIDINE TAG DNA APTAMERS FOR...
              Preview
              Description

              Prokaryotic and eukaryotic expression systems for the production of recombinant proteins are used on a large scale in scientific research. The genetically engineered fusion tags, e.g. histidine tag (His-Tag) are used for fast and efficient purification
              of the desired recombinant proteins. The high affinity of His-Tag to the certain metal ions (cobalt, copper, nickel or zinc) enables the application
              of chromatographic media with the above mentioned ions for the purification
              or immobilization of His-Tagged proteins.

              His-Tag recombinant protein can be detected in western blotting using anti-His mono- and polyclonal antibodies. Short His-Tag can be used to investigate protein-protein interactions in techniques such as pull down assays, immunoprecpitation, co-immunoprecipitation or Far-Western blot analysis.

              DNA aptamers are single-stranded DNA oligonucleotides of approximately 4-100 nucleotides that exhibit a high affinity and specificity to their corresponding ligand. An optimal binding between target molecule and selected aptamer is possible due to the rich secondary and tertiary structures of the latter one.

              The subject of the offer are unique sequences of single-stranded DNA aptamers that recognize His-Tag and their application in biotechnology in analysis of His-Tagged molecules (peptides, proteins or DNA derivatives).


              The offered DNA aptamers can be used for analysis of molecules containing a His-Tag, and in particular to:
              • application as a agonist for anti-histidine antibodies;
              • purification and detection of the target molecules containing a His-Tag.

              In addition to the above applications, DNA aptamers can be used as molecules
              with attached tags, especially fluorescent, and in particular to label the molecular targets containing His-Tag. This type of molecules can be successfully used e.g. to study the interaction between proteins using spectroscopic techniques.


              The offered Anti-Histidine Tag DNA aptamers for biotechnological applications
              is patent pending. Further research and development of the invention are continued at the Faculty of Biochemistry, Biophysics and Biotechnology of the Jagiellonian University. Currently the Centre for Innovation, Technology Transfer and University Development (CITTRU) is looking for entities interested
              in commercial application of the invention.

              Full details Contact close
            • Antimicrobial credit cards identification cards membership cards and identification badges and badge holdersAntimicrobial credit cards identification cards...
                Preview
                Description

                Invention involves embedding antimicrobial disinfectant in commonly used plastic cards-- driver's licenses, identification cards, ATM cards and credit cards -- to reduce transmission of bacteria when the card touches human hands and other surfaces.

                Full details Contact close
              • Apoptosis-Inducing Peptide for Cancer Gene TherapyApoptosis-Inducing Peptide for Cancer Gene Therapy
                  Preview
                  Description

                  Provided is a multifunctional peptide which can induce apoptosis, increase of transfection efficiency with non-viral vectors, and increase of deposition of other proteins in extracellular matrix and therefore resulting in high local concentration of target proteins. The combination of these functions is ideal for improvement of apoptosis-based therapies for cancers. Currently, the inventor has been developing the combinational use of the proposed peptide and Fas-ligand (FasL) for gene therapy of oral and neck tumors. In vivo study using model mice with explanted tumors has shown that this peptide fragment can substantially improve the efficiency of cancer gene therapy using FasL. In fact, some tumors treated by the fused protein of FasL and this peptide completely disappeared.

                  Features and Advantages
                  * E3 and C1 domains of Del1, extracellular matrix (ECM) protein
                  - Proteins fused to the E3 and C1 domains are deposited in the ECM
                  - E3 also increases the endocytosis of transfected genes
                  - E3 induces apoptosis at high concentration
                  * Fusion protein of FasL and E3C1 can be used for improved cancer gene therapy
                  - Local injection of the fusion protein using non-viral vectors
                  - Injected protein is locally concentrated and retained due to its deposition activity
                  - Safer and more economical than therapy by viral vector

                  Possible Applications
                  * Cancer gene therapy

                  Full details Contact close
                • Application of angiotensin1-9 for dendritic cells stimulationApplication of angiotensin1-9 for dendritic cells...
                    Preview
                    Description

                    The subject of the offer is an application of a biogenic peptide to stimulate chemotaxis of dentritic cells, and thereby to modulate the immune response. The increase in migration capacity of these cells of clinical relevance and may be useful in treatment of autoimmune diseases, viral infections and atherosclerosis, as well as during preparation of cancer vaccines ex vivo.

                    Full details Contact close